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Interactions between neurokinin B and kisspeptin in
mediating estrogen feedback in healthy women
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Robert P Millar3, Richard A Anderson1
1MRC Centre for Reproductive Health, The Queen’s Medical Research Institute, University of Edinburgh,
47 Little France Cres, Edinburgh EH16 4TJ, UK; 2Endocrine Research Unit, Center for Translational
Science Activities, Mayo Clinic, Rochester, MN, 55905, USA; 3Mammal Research Unit and Centre for
Neuroendocrinology, University of Pretoria, 0028 Pretoria, S Africa and MRC Receptor Biology Unit,
Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, 7925 Observatory, S
Africa.
Context: Kisspeptin and neurokinin B (NKB) are obligate for normal gonadotropin secretion, but
their hierarchy is unexplored in normal women.
Objective: To investigate the interaction between kisspeptin and NKB on estrogen-regulated LH
secretion.
Design:Women were treated with NK3R antagonist followed by transdermal estradiol to induce
LH secretion 48hr later, with kisspeptin-10 or vehicle infusion during estrogen administration in a
two-way cross-over study.
Setting: Clinical Research Facility.
Patients or other participants: Healthy females with regular menses.
Intervention(s):NK3Rantagonist AZD4901 40mgbdorallywas taken fromcycle day 4–6 for 6 days
(n10, with 10 no treatment controls). Transdermal estradiol patches (200g/day) were applied
after 5 days of NK3R antagonist treatment. At 24hr estradiol treatment, womenwere randomised
to 7hr kisspeptin-10 (4g/kg/hr) or vehicle iv infusion, with the alternate infusion in a subsequent
cycle.
Main outcome measure(s): Plasma gonadotropin and estradiol secretion.
Results: Followingan initial suppression, LH secretionwas increased48hrafter estradiol treatment.
Kisspeptin-10 increased LH secretion during the inhibitory phase, and LH remained elevated be-
yond thediscontinuationof kisspeptin-10 infusion.NK3Rantagonist decreased LHpulse frequency
(0.50.2 vs 0.70.2 pulses/hr, p0.05) and stimulated FSH response to kisspeptin-10 infusion
(10.711.0 vs 5.03.6 IU/l, p0.05) with a non-significant rise in LH. The duration of LH response
was blunted, with LH being lower at 48hr (7.54.8vs 15.011.4 IU/l, p0.05).
Conclusions: These data demonstrate that NKB signalling regulates GnRH/LH secretion in normal
women,and ispredominantlyproximal tokisspeptin inmediatingestrogenicpositiveandnegative
feedback on LH secretion.
Sex steroid feedback regulates the pulsatile release ofhypothalamic GnRH, thereby controlling gonado-
tropin (LH and FSH) secretion and gonadal function (1).
During the early follicular phase of the menstrual cycle
estrogen feedback is inhibitory, but during the late follic-
ular phase, estrogenic feedback stimulates GnRH secre-
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tion, culminating in the midcycle LH surge that triggers
ovulation. Neuroendocrine mechanisms involved in these
pathways and the switch from negative to positive estro-
gen feedback in the late follicular phase remain unclear.
Kisspeptin and neurokinin B (NKB), neuropeptides
partially coexpressed by a population of neurons that also
express the opiate, dynorphin, are now recognized as cen-
tral to the regulation of human reproduction. Patients
with loss-of-function mutations in kisspeptin, NKB, or
their respective receptors (KISS1R and NK3R) show hy-
pogonadotropic failure of pubertal progression (2–5),
while activating mutations in kisspeptin receptor are as-
sociated with precocious puberty (6). Experimental char-
acterization of the relative roles played by kisspeptin and
NKB, as well as their functional hierarchy, has been
largely carried out in nonhuman models (7–11). In pa-
tients with genetic defects inactivating NKB signaling, ex-
ogenous kisspeptin, administered using a regimen shown
to be maximally stimulatory in healthy volunteers (12),
restored LH pulse frequency to normal (13). This, and
concordant data from animal models (7, 8), has led to the
conclusion that central NKB signaling is functionally up-
stream of kisspeptin. Data from animal studies of admin-
istration of exogenous NKB are discordant, with both
stimulatory and inhibitory effects on LH secretion being
reported (9–11), whereas it elicited little effect on gonad-
otropin secretion in a human study (14).
In women, gonadotropin response to exogenous kiss-
peptin is dependent on the sex-steroid milieu (15) and is
greatest in the late follicular phase of the menstrual cycle
(16–18), suggesting a role for kisspeptin in the preovula-
tory positive estrogenic drive to GnRH/LH secretion. Ex-
ogenous kisspeptin can increase LH secretion sufficiently
to induce oocyte maturation following ovarian stimula-
tion (19), but the role of kisspeptin in physiological pos-
itive estrogen feedback is unclear. Involvement of kisspep-
tin in the ovulatory LH surge in rats and sheep is
demonstrated by loss the LH surge during kisspeptin re-
ceptor antagonist treatment (20, 21). The effect of kiss-
peptin appears largely through an increased frequency of
pulsatile GnRH secretion (12, 22, 23), which preferen-
tially stimulates LH over FSH secretion from gonadotro-
phs (24). Recent data from animal models indicate that
administration of an NKB receptor antagonist can slow
LHpulsatility (25), and this has also been demonstrated in
women with polycystic ovary syndrome (26) where LH
pulse frequency is often increased.
We have investigated the role of kisspeptin and NKB
signaling in the regulation of positive estrogen feedback in
women by administration of an NKB receptor antagonist
and an infusion of kisspeptin-10 during exogenous estro-
gen administration.We hypothesized that in this model of
estrogen-induced LH secretion, kisspeptin would aug-
ment LH secretion, and that pharmacological blockade of
NKB signaling would reveal the functional hierarchy be-
tween kisspeptin andNKB in generating the preovulatory
LH surge, and in modulating GnRH/LH pulsatility.
Materials and Methods
Participants
Twenty healthywomen, aged 18–45 years with regularmen-
strual cycles (25–35 days) were recruited from the community to
this study,whichwas approved by South East ScotlandResearch
Ethics Committee (Ref: 09/S1101/67); all volunteers provided
informed written consent. Subjects were not taking steroidal
contraception, had normal physical examination, and full blood
count, renal function, electrolytes, liver function and electrocar-
diogram (ECG) were within normal limits.
Study drugs
Kisspeptin-10was custom synthesized underGMP standards
(Bachem GmBH,Weil am Rhein, Germany) (12). 1 mg kisspep-
tin-10 was dissolved in 5 ml sterile normal (0.9%) saline imme-
diately before infusion. The syringe and line for infusion were
first coated for 30 minutes with kisspeptin-10 to minimize pep-
tide loss from adherence to the plastic. Sterile normal saline was
infused as vehicle. The specific neurokinin-3 receptor (NK3R)
inhibitor AZD4901, formulated as 20 mg tablets, was gifted by
AstraZeneca, UK. Transdermal patches releasing 200 g 17
estradiol per 24 hours (Janssen-Cilag Buckinghamshire, UK)
were used as exogenous estradiol treatment (27).
Protocol
To standardize estrogen exposure and the onset of increased
LH secretion,we used amodel of follicular phase administration
of transdermal estradiol (200 g/d), which initially suppresses
then at 48 hours increases LH secretion (28). In preliminary
studies (Supplemental Figure 1) we confirmed that LH secretion
at 48 hours is increased to the same extent if the patches were
removed at 32 hours or continued till 72 hours: for the main
study therefore patches were removed at 32 hours. Sample size
was based on previous proof of concept mechanistic studies (12,
15). Twenty women were randomly allocated to NK3R antag-
onist (AZD4901) 40 mg oral twice daily starting from cycle day
4–6 for 6 days, or no treatment (Figure 1). Two transdermal
estradiol patches were administered after 5 days (time 0 hours),
in the late follicular phase (cycle day 9–11, according to the day
of starting AZD4901). At 24 hours of estradiol treatment vol-
unteers attended our clinical research facility for 8 hours. After
anhourofbaseline sampling, volunteerswere randomized (using
sealed envelopes) to receive a continuous intravenous (IV) infu-
sion of kisspeptin-10 (4 g/kg/hr) or vehicle for 7 hours. In the
NK3R antagonist treatment group, the last dose of AZD4901
was on the morning of kisspeptin-10 or vehicle administration.
Estradiol patches were removed at the end of the infusion ie, 32
hours after application. Volunteers attended for further mea-
surement of reproductive hormones at 48 and 72 hours. In a
subsequent menstrual cycle, all women returned to receive the
alternate infusion of kisspeptin-10 or saline. Those receiving
NK3R antagonist had at least one wash out cycle between treat-
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ment cycles. To compare the effect of exogenous vs endogenous
estrogenonkisspeptin-10 response, another groupof tenwomen
received IV kisspeptin-10 (4 g/kg/hr) infusion for 7 hours on
cycle day 10–12 without exogenous estrogen treatment, with
reproductive hormone measurements at equivalent time points.
Blood sampling and hormone assays
Peripheral venous blood was sampled for LH, FSH and es-
tradiol in the treatment group on the day of commencing NK3R
antagonist and in both control and treatment groups before es-
tradiol treatment (0 hour) and then at 24, 32, 48 and 72 hours.
During the 8 hour visit, blood samples were collected via an
indwelling iv cannula at 10 minutes intervals for assessments of
LH pulsatility; FSH was measured hourly. Blood samples were
centrifuged at 4°C for 10minutes at 3000 rpm and serum frozen
at –20°C or below until analysis. LH and FSH were determined
by ELISA as previously described (12). 17-estradiol was mea-
sured by ELISA (Demeditec Diagnostics, Kiel, Germany). Inter-
assay and intra-assay coefficient of variation for all hormones
was5%at the concentrationsmeasured.Lowerdetection limit
for LH and FSH was 0.1 IU/l and for estradiol 20 pmol/l.
Statistical analysis
Analysis of variance (ANOVA) was used to analyze prelim-
inarydataonLHchangeswith time in themodel. For theprimary
endpoints, hormone concentrationswere compared between the
four treatment groups at specific time points usingANOVAwith
repeated measures as appropriate. If there was overall signifi-
cance, post hoc analysis was performed with Bonferroni’s cor-
rection for multiple comparisons, comparing all four treatments
simultaneously at each time point. The relationship between the
timingof peakLHand treatmentwas assessedby2 test. Pearson
correlation coefficient was computed to assess the relationship
between estradiol concentrations and LH response to
kisspeptin-10.
The number of LH pulses, secretory mass of LH per pulse,
basal (nonpulsatile) andpulsatile (integral of dual amplitude and
frequency regulation) LH secretion were
identified by an established deconvolu-
tional algorithm with cluster analysis
(93% sensitivity and specificity) (29, 30)
blinded to treatment allocation.Approx-
imate entropy (ApEn), a measure of or-
derliness, was also estimated for the pat-
tern of LH secretion. Deconvolutional
estimates and mean hourly hormone
changes were not calculated for one
woman in each group, as full 8 hour sam-
pling data were not obtained. ANOVA
was used to assess changes in LH pulsa-
tility parameters between the 4 groups,
with post hoc testing as above.
Data are presented as mean  SD.
Data not normally distributed were log-
transformed prior to statistical analysis,
resulting in a distribution that approxi-
mated a normal distribution.Differences
were regarded as significant at a two-
sided P  .05. The statistical software
package GraphPad Prism (GraphPad,
San Diego, California) was used.
Results
Baseline age, BMI and the menstrual cycle length were
comparable between the subjects in the control and the
treatment group, as were baseline LH, FSH and estradiol
levels in vehicle and kisspeptin-10 cycles within the group
(Table 1).
Model validation for estrogen-induced LH
secretion
Treatment with exogenous estrogen for 32 hours in-
creased serum estradiol concentrations as expected (P 
.0001) (Supplemental Figure 1). Serum LH was initially
suppressed at 32 hours of estrogen treatment, then in-
creasedat48hourswhichpersistedat 72hours (allP .05
vs 0 hours). FSH concentrations were significantly lower
at 24 (P  .01) and 32 hours (P  .0001) but were not
higher at 48 and 72 hours compared to baseline. This
confirms that with this regimen, estrogenic negative feed-
back is followedby increasedLHsecretion, thus standard-
izing estrogen exposure and the time course of changes in
LH secretion.
Kisspeptin-10 stimulates gonadotropin secretion
During estrogen administration, kisspeptin-10 stimu-
lated LH secretion to 16.4  12.4 IU/l at the end of infu-
sion vs 2.9  1.0 IU/l following vehicle administration
(P .0001) (Figure 2A). The time course of this response
is shown in Figure 3A. Kisspeptin-10 induced LH secre-
tion persisted beyond the discontinuation of the infusion
Figure 1. Study protocol diagram. Follicular phase administration of transdermal estradiol
was used to induce LH secretion 48 hours later as a model of the midcycle LH surge in women.
Ten healthy women were administered NK3R antagonist AZD4901 from cycle day 4–6 for 6
days, matched to ten women having no treatment. Transdermal estradiol was applied after 5
days. 24 hours later, women were randomized to 7 hour of kisspeptin-10 or vehicle infusion,
returning in a subsequent cycle for the alternate infusion. Reproductive hormones were
measured throughout the study and LH pulsatility assessed during 10 minute blood sampling for
8 hours.
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with higher peak LH compared to controls at 48 hours
(9.3  1.9 vs 21.6  13.0 IU/l, P  .007) (Supplemental
Table 1). Clarification of the impact of exogenous estra-
diol on this response was demonstrated in a separate
group of women receiving kisspeptin-10 infusion only in
the late follicular phase without exogenous estrogen ad-
ministration, who showed a similar acute increase in LH
secretion correlating positively with estradiol concentra-
tion (r20.63, P  .006), but of a shorter duration (48
hours: 6.8  5.8 IU/l vs 15.0  11.4 with estrogen treat-
ment, P .01; Supplemental Figure 2). All subjects in the
endogenous estrogen group had peak LH at the end of
kisspeptin-10 infusion, whereas in exogenous estrogen-
treated subjects the kisspeptin-10 induced peak LH per-
sisted beyond kisspeptin-10 infusion with 50%of women
havingpeakLHat32hours and50%at48hours (P .01,
Supplemental Table 1).
FSH secretionwas also significantly higher at the endof
kisspeptin-10 infusion compared to vehicle in the control
group (P  .05) but not different to baseline (0 hours;
Figure 2B, 3B). As expected with this model of exogenous
estradiol administration, estradiol concentrations were
similar in kisspeptin-10 and vehicle-infused controls (Fig-
ure 2C).
NK3R antagonist has differential effects on LH and
FSH secretion
Serum LH levels did not change after 5 days of NK3R
antagonist treatment (before the estradiol patches were
applied) when compared to either pretreatment concen-
trations (preNK3Ra5.01.8 vs 5 daysNK3Ra6.64.0
IU/l, ns) or to controls (Figure 2A). Overall there was no
difference inLHconcentrations and the timingof peakLH
in controls vs NK3Ra-treated women (Supplemental Ta-
ble 1 and Figure 2A). To detect subtle changes in hormone
secretion potentially overlooked by single time point
blood sampling, analysis of hourly LH for 8 hours post
dose showed that overall LH secretion was lower in
Table 1. Baseline characteristics of women in the control and the treatment group undergoing vehicle and
kisspeptin-10 infusion. Data are shown as mean  SD; ns, not significant. Note that baseline data on control and
treatment groups in lower part of the table reflect sampling at different stages of the menstrual cycle
Control group Treatment (NK3Ra) group p value
n 10 10
Age (years) 35  5.8 35  5.4 ns
BMI (kg/m2) 25  4.6 28  6.9 ns
Cycle length (days) 29  1.8 28  1.4 ns
Vehicle cycle Kp-10 cycle p
value
Vehicle cycle Kp-10 cycle p value
Menstrual cycle day 9.2  0.8 9.4  0.8 ns 4.4  0.5 4.8  0.8 ns
LH (IU/liter) 4.8  2.1 5.6  2.0 ns 5.0  1.8 4.9  1.8 ns
FSH (IU/liter) 4.3  1.2 5.3  2.6 ns 6.2  1.8 5.5  1.3 ns
Estradiol (pmol/liter) 274  126 287  157 ns 121  54 154  47 ns
Figure 2. Comparison of mean LH (A), FSH (B) and estradiol (C)
response to an infusion of kisspeptin-10 and vehicle in ten control and
ten NK3R antagonist-treated women in the model of estrogen-induced
LH secretion. Two estradiol patches releasing a total of 200 g
estradiol/d were applied between 0 and 32 hours. The infusion period
of kisspeptin-10 and vehicle was between 24 and 32 hours. Data
presented as mean  SD. *, P  .05; ****, P  .0001.
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NK3Ra-treatedwomen compared to controls (P .0001,
Figure 3A), although post hoc analysis indicated no sig-
nificant differences in LH levels at any individual hourly
time point.
FSH concentrations appeared higher throughout treat-
mentwithNK3Rantagonist compared to controls (Figure
2B) and were significantly higher in NK3Ra-treated
women throughout the eight-hourperiod (ie, during saline
infusion, P  .0001) (Figure 3B). This may reflect that
serum estradiol concentrations were significantly lower
after 5daysof treatmentwithNK3Rantagonist compared
to controls (P  .05) (Figure 2C) and comparable to es-
tradiol levels beforeNK3Rantagonist administration (pre
NK3Ra:12154vs14587pmol/l after5daysNK3Ra,
ns).
Effect of NK3R antagonist on the gonadotropin
response to kisspeptin-10
NK3R antagonist nonsignificantly increased kisspep-
tin-10 stimulated LH secretion at 32 hours (21.6  17.8
with NKB antagonist vs 16.4  12.4 IU/l kisspeptin-10
alone, P  .41) (Figure 2A, 3A). The FSH response to
kisspeptin-10 was however significantly more pro-
nounced in the presence of NK3Ra (10.7 11.0 vs 5.0
3.6 IU/l at 32h, P  .05 Figure 2B; and throughout the 7
hour infusion: P  .0001 Figure 3B).
However, NK3Ra blunted the duration of kisspep-
tin-10 induced LH secretion, with significantly lower LH
at 48 hours (15.0 11.4 vs 7.5 4.8 IU/l, P .05) when
compared to kisspeptin-10 infused controls, whereas FSH
showed no significant difference
(Figure 2). There were related
changes in the timing of the LH peak
(although not statistically signifi-
cant), which was at 32 hours in 9/10
NK3Ra-treated women in response
to kisspeptin-10 infusion, compared
with kisspeptin-10 treated controls
whose LH peak timing was evenly
divided between 32 and 48 hours
(Supplemental Table 1).
NK3R antagonist impedes
estradiol dependent kisspeptin-
10 response
The relationship between LH re-
sponse to kisspeptin-10 and estra-
diol exposure, and the influence
thereon of NK3Ra treatment, was
investigated by analyzing LH con-
centration at the end of kisspep-
tin-10 infusion in relation to endog-
enous estradiol concentrations at 0
hours (ie, before transdermal estradiol application). There
was a strongpositive correlation in controls (r20.75,P
.001) (Figure 4). However, inNK3Ra-treatedwomen, the
LHresponse tokisspeptin-10 showedno such relationship
(r20.007, ns). Very similar results were obtained when
the analysiswasbasedon estradiol concentrations after 24
hours of patch administration (r20.65, P .005 in con-
trols; r20.03, ns in NK3Ra-treated women).
Interaction between NK3R antagonist and
kisspeptin-10 in regulating LH pulsatility
LH pulse frequency increased from 0.7 0.2 pulses/hr
in vehicle cycle to 1.00.2 pulses/hr during kisspeptin-10
infusion (P  .01) (Figure 5A, B). NK3R antagonist re-
duced LH pulsatility to 0.5  0.2 pulses/hr (P  .05 vs
vehicle-infused controls), but administration of kisspep-
tin-10 to NK3Ra-treated women restored LH pulse fre-
quency to that observed in kisspeptin-10-infused controls.
Thus while NK3Ra slowed LH pulsatility in estrogen
treatedwomen, it did not affect the response to kisspeptin-
10, indicating that kisspeptin effects are downstream of
NKB signaling.
Secretory mass of LH per pulse was increased similarly
during infusion of kisspeptin-10 comparedwith vehicle in
both control (P  .05) and NK3R antagonist treated
women (P .01) (Figure 5C). NK3Ra antagonist did not
reduce LH secretory mass per pulse.
Consistent with increased LH pulse frequency, basal
LH secretion decreased and pulsatile LH secretion in-
Figure 3. LH (A) and FSH (B) levels an hour pre and during 7 hours of vehicle or kisspeptin-10
infusion in the control group (n  9) and in the treatment (NK3R antagonist) group (n  9). The
infusion period of kisspeptin-10 and vehicle was between 24 and 32 hours of estrogen
administration. Data presented as mean  SD. Statistical analysis by 2-way ANOVA determined
statistically lower LH levels between vehicle and NK3Ra-treated women (P  .0001), although
Bonferroni’s post hoc multiple comparison test found no significant changes at specific time
points. For vehicle vs kisspeptin-10 infused controls: *P  .05, ****P  .0001. For kisspeptin-10
infusion in controls vs NK3Ra: P  .01. For vehicle vs NK3Ra: P  .05, P  .01. For vehicle vs
kisspeptin-10 in NK3Ra-treated women: P  .05, P  .01, P  .001, P  .0001.
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creased during kisspeptin-10 infusion in the control group
(P  .05 vs vehicle; Figure 5D, E). Basal LH secretion
appeared lower in NK3Ra-treated women when com-
pared to controls but there was no effect on pulsatile LH
secretion. Kisspeptin-10 induced the same changes in
NK3Ra treated women as in controls, with no change in
basal and an increase in pulsatile LH
secretion (P  .0001).
The regularity of LH secretory
patternwasassessedbyapproximate
entopy (ApEn). Both kisspeptin-10
infusion and NK3Ra separately im-
posed greater orderliness (lower
ApEn) in LH secretion (P .05; Fig-
ure 5F).Thiswas increased further in
NK3Ra- treated women during kiss-
peptin-10 infusion (P  .0001 vs
NK3Ra alone; Figure 5F).
Discussion
In a model of LH modulation by es-
trogen administration inwomen, ex-
ogenous kisspeptin-10 stimulated
LH secretion, the extent of which re-
flected estradiol concentrations.
Pharmacological blockage of NKB-NK3R signaling
slowed LH pulsatility and shortened the duration of kiss-
peptin-mediatedLH secretionwith ‘sharpening’ of the LH
response, and strikingly abolished the relationship be-
tween estradiol and LH response to kisspeptin. Taken to-
Figure 4. Correlation between endogenous estradiol and LH response to
kisspeptin-10 in controls and NK3R antagonist treated women. Kisspeptin-10
response on LH secretion is positively related to endogenous estradiol levels, while this
correlation is not seen during NK3R antagonist treatment. Analysis of residuals demonstrated
normal distribution.
Figure 5. Analysis of 8 hour LH secretory pattern during vehicle and kisspeptin-10 in controls and NK3Ra-treated
women. A, Illustrative LH pulse profile from one subject undergoing vehicle (green triangles), NK3R antagonist (purple circles), kisspeptin-10
(red diamonds) and NK3R antagonist followed by kisspeptin-10 (blue squares) treatment visits. Mean LH pulse frequency (B), secretory mass of LH
per pulse (C), basal (nonpulsatile) LH secretion (D), pulsatile LH secretion (E) and the relative orderliness/regularity of LH secretory pattern (F)
during vehicle and kisspeptin-10 infusion with (n  9) and without (n  9) pretreatment with NK3R antagonist. Mean  SD. *, P  .05; **, P 
.01; ****, P  .0001.
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gether, these data support a central role for kisspeptin in
the modulation of GnRH/LH secretion, and while NKB
signaling is largely upstream of kisspeptin as previously
reported (13), both pathways interact in determining the
timing and characteristics of estrogenic negative and pos-
itive feedback on LH secretion.
The stimulatory effect of exogenous kisspeptin on LH
secretion in women is dependent on the sex steroid envi-
ronment (15–18). This response is initially limited but in-
creases markedly in the late follicular phase of the men-
strual cycle when estradiol levels are rising (16–18). For
most of the cycle, GnRH and thus LH secretion are in-
hibited by negative feedback from estradiol (and proges-
terone in the luteal phase), thus the low responsiveness to
kisspeptin administration in previous studies is consistent
with endogenous kisspeptin signaling being suppressed by
the inhibitory steroidal actions, presumably at the GnRH
neuron and/or gonadotroph level. Conversely, the en-
hanced LH response in the later follicular phase may in-
dicate the development of increased endogenous kisspep-
tin signaling in the lead up to the midcycle surge. This is
supported by animal studies, where kisspeptin expression
is highest following an estrogen challenge in the antero-
ventral periventricular nucleus (the site of positive estro-
gen feedback in rodents) in ovariectomized mice (31) and
at the time of GnRH/LH surge in sheep (32), but is pre-
vented by administration of kisspeptin receptor antago-
nist (20, 21). The present data suggests a role of estradiol
in modulating LH response to kisspeptin-10 infusion,
which persisted well beyond the pharmacokinetic clear-
ance of the exogenous kisspeptin-10. The striking positive
relationship between estradiol concentration in the late
follicular phase and the LH response to kisspeptin-10 in-
fusion lends further support for the involvement of kiss-
peptin in estrogen feedback, as recently demonstrated for
kisspeptin-54 (33).
The present data demonstrate that NK3R antagonist
treatment, in an environment of high estrogenic negative
feedback, reduced LH secretion and pulse frequency,
while in the presence of kisspeptin-10 had a stimulatory
effect on the secretion of both gonadotropins, but with a
shorter duration of LH response. Hitherto, NK3R antag-
onists have beendemonstrated to suppress LHsecretion in
states of high LH output, such as in women with PCOS
(26), or in the ovariectomized ewe and castrate monkeys
(25, 34), and in intact femalemonkeys adelayof surge-like
but no decrease in basal LH secretion was observed (25).
Although it appears that the suppression of LH secretion
by the present dose and regimen lasted only a few hours,
this was sufficient to significantly lower estradiol concen-
trations after 5 days of NK3R antagonist treatment (ie,
prior to the estrogenic treatment) compared to controls.
While this demonstrates a role ofNKB in the regulation of
LH secretion, NK3R antagonist had no effect on the tim-
ing of peak LH secretion in this model of estrogen admin-
istration,which is consistentwith a lack of effect ofNK3R
antagonist on the estrogen inducedLHsurge seen in ovari-
ectomised ewes (34). Themechanisms critical for progres-
sion to positive estrogen feedback therefore appear to be
largely independent of NKB but dependent on kisspeptin,
consistent with rodent neuroanatomical data (31, 35). A
recent study using a different NK3R antagonist in normal
women also showed a temporary suppression of LH levels
lasting few hours post dosing, but no overall decrease in
basal LH secretion following treatment throughout the
follicular phase (34). NK3Ra did, however, delay LH
surge in some women, probably as a consequence of de-
layed preovulatory estradiol rise, but the study did not
assess the effect of neurokinin B antagonism at the time of
the switch from negative to positive estrogen feedback,
when NKB might be no longer critical (36). Unlike in the
present study, no effect of NK3Ra on FSH secretion was
observed (35).
We have previously demonstrated that infusion of kiss-
peptin-10 can restore LH pulsatile secretion in men and
women with inactivating mutations in NKB signaling, in-
dicating that kisspeptin is functionally downstream of
NKB in LHpulse generation (13). This is supported by the
inability of the NK3R agonist senktide to stimulate LH
secretion inKiss1rknockoutmice (7).Consistentwith this
overall hierarchy, NKB antagonism (active during kiss-
peptin-10 administration as half life of AZD4901 is 8.5
hours (37)) did not prevent the stimulatory effect of kiss-
peptin-10 infusiononLHsecretion.NKBantagonist how-
ever shortened the LH response to kisspeptin-10, affecting
its timing by reducing the variability of peak LH secretion,
and disrupted the relationship between LH response and
estradiol concentrations. These findings suggest a more
complex interaction than a linear pathway between those
neuropeptides at the timeof themidcycleLHsurge, but are
also consistent with NK3R antagonist reducing endoge-
nous kisspeptin stimulation of GnRH as a contribution to
the observed effect.
LH pulse frequency increases in the late follicular
phase, culminating in the midcycle LH surge (38). Exog-
enous kisspeptin stimulates pulsatile LH secretion (12, 13,
22, 23, 39), but its role as a potential contributor to pos-
itive estrogen feedback has not been previously investi-
gated. In this study, the increase in LH secretion during
kisspeptin-10 infusion included increased LH pulse fre-
quency and mass-per-secretory pulse. This resulted in a
larger proportion of total LH secretion occurring in pul-
satile bursts, and the regularity of LH secretory pattern
showed greater orderliness in the lead up to the stimula-
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tory phase of response to estrogen. Deconvolution anal-
ysis also indicated changes in thenatureof thepulsatileLH
secretion following NK3R antagonist administration,
with reduced basal secretion and ApEn, indicating a more
orderly, slowed pattern of LH and by inference GnRH
secretion. The increase in LH pulse frequency resulting
from kisspeptin-10 infusion and the slowing in LH pul-
satility with NK3R antagonist administration both in-
creased the regularity and orderliness of LH secretion and
may be the basis for the reduced variability in the timing
of peak LH secretion as well as shortened duration of
stimulated LH secretion in response to kisspeptin-10.
Consistent with some aspects of our findings, estrogen-
induced LH surges were preserved in ovariectomized
NK3R antagonist-treated ewes, although the onset-to-
peak time was delayed (34). In sheep, the NK3R agonist
senktide increased LH secretion, resembling ‘surge-like’
LH levels (9), while in monkeys, NK3R antagonist abol-
ished LH surge, ovulation and subsequent progesterone
rise (25). While our data primarily indicate that NKB sig-
naling is largely upstream of kisspeptin signaling in me-
diating estrogenic positive effects, it clearly has a modu-
latory role in determining the pattern and duration of
GnRH secretion during estrogen positive feedback.
A stimulatory effect of kisspeptin alone on FSH has
beenminimal and inconsistent in previous studies (16–18,
40), but was robustly demonstrated in this model andwas
not prevented by NK3R antagonist treatment. NK3R an-
tagonist also increased FSH secretion, and markedly aug-
mented stimulation by kisspeptin-10. These findings are
consistent with well-established data from animal models
showing that high GnRH pulse frequency favors LH se-
cretion while low pulse frequency favors FSH secretion
(24), and that this is the main drive to follicular estrogen
production, the reduction in both ofwhich (and presumed
reduced inhibinproduction) is likely tohave resulted in the
observed increased FSH secretion. The differential effects
of NK3Ra on FSH vs LH response to kisspeptin-10 are
also similar to the effects in patients with NKB defects
(13).
While the present study has clear strengths (the use of
specific neurokinin-3 receptor antagonist, detailed LH
pulse profiling andblindedpulse analysis), there areweak-
nesses. The sample size is small, and placebo was not ad-
ministered to the control group receiving no NK3Ra. The
limited LH suppression by the NK3R antagonist might be
due to the small sample size and thedoseofAZD4901may
be low compared to those used in animal studies, limiting
the response (25). Statistical analyses included adjustment
for alpha for multiplicity of comparisons but studies such
as these should be regarded as mechanistic explorations.
Moreover, this model of LH secretion after exogenous
estrogen administration may not fully replicate physio-
logical positive estrogen feedback in the preovulatory
state.
In summary, using estrogen to standardize LH secre-
tion in women to model the midcycle LH surge, we have
shown that the increase in LH secretion by kisspeptin-10
infusion is related to estradiol exposure. We show for the
first time that NK3R antagonist reduced LH pulsatility in
healthy women. Assessment of the interaction between
kisspeptin and NKB showed that the duration of kisspep-
tin-mediated LH secretion was shortened by the NK3R
antagonist, and the quantitative relationship with estra-
diol exposure abolished. These data thus indicate that
NKB pathways regulate GnRH/LH secretion in women,
are predominantly upstreamof kisspeptin signaling inme-
diating estrogen feedback, but modify this kisspeptin re-
sponse. This extends our understanding of these critical
events in human reproduction.
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